5,6-Dihydroxy-3-phenyl-1-aminomethylisochroman | 130465-45-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5,6-Dihydroxy-3-phenyl-1-aminomethylisochroman
• 英文别名: (1R,3S)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-isochromene-5,6-diol
• CAS: 130465-45-1
• 化学式: C₁₆H₁₇NO₃
• 分子量: 271.31
• InChiKey: SUHGRZPINGKYNV-GJZGRUSLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  75.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
  申请人：University of Canberra

  公开号：US10874629B2

  公开（公告）日：2020-12-29

  Disclosed are compositions comprising levodopa and an antioxidant for inhibiting the development or progression of visual disorders inclusive of visual disorders associated with diabetic retinopathy or Parkinson's disease, and myopia.

  所公开的是包含左旋多巴和抗氧化剂的组合物，用于抑制视觉障碍（包括与糖尿病视网膜病变或帕金森病相关的视觉障碍）和近视的发生或发展。
• METHODS FOR IDENTIFYING RESPONDERS TO DOPAMINERGIC NEURONAL ENHANCING THERAPIES FOR THE TREATMENT OF ELEVATED HEART RATE AND METABOLIC OR CARDIOVASCULAR CONDITIONS
  申请人：VeroScience LLC

  公开号：US20170340271A1

  公开（公告）日：2017-11-30

  Methods for identifying responders to agents that increase brain dopaminergic neuronal activity for the treatment of metabolic and cardiovascular disease and for treating elevated heart rate and metabolic disease or dysglycemia in subjects with type 2 diabetes.
• OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER
  申请人：University of Canberra

  公开号：US20190151270A1

  公开（公告）日：2019-05-23

  Disclosed are compositions comprising levodopa and an antioxidant for inhibiting the development or progression of visual disorders inclusive of visual disorders associated with diabetic retinopathy or Parkinson's disease, and myopia.
• OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER
  申请人：University of Canberra

  公开号：US20210077443A1

  公开（公告）日：2021-03-18

  Pharmaceutical ocular compositions include levodopa, an antioxidant and an aqueous carrier. A wide selection of antioxidants can be included in the compositions, such as ascorbic acid, phenolic acids, sorbic acid, sodium bisulfite, sodium metabisulfite, acetyl cysteine, sodium thiosulfate, ethylene diamine tetraacetic acid, sodium nitrite, ascorbyl stearate, ascorbyl palmitate, alpha-thioglycerol, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol or vitamin E, tocopherol acetate, dibutylhydroxytoluene, soybean lecithin, sodium thioglycolate, butylhydroxyanisole, propyl gallate, uric acid, melatonin, and thiourea, as well as salts and combinations of these antioxidants.
• METHODS OF INHIBITION
  申请人：University of Canberra

  公开号：US20220047529A1

  公开（公告）日：2022-02-17

  Uses of dopamine, deuterated dopamine, a deuterated dopamine derivative such as deuterated L-dopa, or a pharmaceutically acceptable salt thereof, in inhibiting the development or progression of visual disorders, such as myopia, or a visual disorder associated with diabetic retinopathy or Parkinson's disease, are provided.